Antiviral immunotherapy: Emerging approaches with relevance to cutaneous disease

Expert Review of Dermatology

Volumn 2, Issue 5, 2007, Pages 619-627

  Holzer, Aton M ^a   Levis, William R ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CpG ODN; Haptens; Heat shock proteins; Imiquimod; Poly(I:C); Resiquimod; Th17; Toll like receptors; Topical sensitizers

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; AMPLIGEN; ANTIVIRUS AGENT; CPG 10101; CPG OLIGODEOXYNUCLEOTIDE; DIPHENCYPRONE; FOMIVIRSEN; HAPTEN; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 65; IMIDAZOQUINOLINE DERIVATIVE; IMIQUIMOD; MESSENGER RNA; PATTERN RECOGNITION RECEPTOR; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN E7; R 851; RECOMBINANT HEAT SHOCK PROTEIN 70; RECOMBINANT PROTEIN; RESIQUIMOD; SQUARIC ACID DIBUTYL ESTER; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; BCG VACCINATION; CELLULAR IMMUNITY; CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; DRUG HALF LIFE; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENE TARGETING; GENITAL HERPES; HEPATITIS C; HERPES SIMPLEX; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RETINITIS; REVIEW; SKIN DISEASE; T LYMPHOCYTE; VERRUCA VULGARIS; VIRUS INFECTION; VIRUS REPLICATION;

EID: 35948933033     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.2.5.619     Document Type: Review

References (106)

1. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv. Exp. Med. Biol. 560, 11-18 (2005).
2. Seth RB, Sun L, Chen ZJ. Antiviral innate immunity pathways. Cell Res. 16(2), 141-147 (2006).
3. Paladino P, Cummings DT, Noyce RS, Mossman KL. The IFN-independent response to virus particle entry provides a first line of antiviral defense that is independent of TLRs and retinoic acid-inducible gene I. J. Immunol. 177(11), 8008-8016 (2006).
4. Bowie AG. Translational mini-review series on Toll-like receptors: recent advances in understanding the role of Toll-like receptors in anti-viral immunity. Clin Exp Immunol. 147(2), 217-226 (2007).
5. Flacher V, Bouschbacher M, Verronese E et al. Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J. Immunol. 177(11), 7959-7967 (2006).
6. Renn CN, Sanchez DJ, Ochoa MT et al. TLR activation of Langerhans cell-like dendritic cells triggers an antiviral immune response. J. Immunol. 177(1), 298-305 (2006).
7. Pivarcsi A. Toll-like receptor 9-independent suppression of skin inflammation by oligonucleotides. J. Invest. Dermatol. 127(4), 746-748 (2007).
8. Lebre MC, van der Aar AM, van Baarsen L et al. Human keratinocytes express functional Toll-like receptor 3,4,5 and 9. J. Invest. Dermatol. 127(2), 331-341 (2007).
9. Galiana-Arnoux D, Imler JL. Toll-like receptors and innate antiviral immunity. Tissue Antigens 67 (4), 267-2 76 (2006).
10. Zinkernagel RM, Doherty PC. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or serniallogeneic system. Nature 248(450), 701-702 (1974).
11. Barton GM. Viral recognition by Toll-like receptors. Semin. Immunol. 19(1), 33-40 (2007).
12. Bieback K, Lien E, Kiagge IM et al. Hemagglutinin protein of wild-type measles virus activates coll-like receptor 2 signaling. J. Virol. 76(17), 8729-8736 (2002).
13. Jude BA, Pobezinskaya Y, Bishop J et al. Subversion of the innate immune system by a retrovirus. Nat. Immunol. 4(6), 573-578 (2003).
14. Hasan UA, Bates E, Takeshita F et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178(5), 3186-3197 (2007).
15. Harte MT, Haga IR, Maloney G et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197(3), 343-351 (2003).
16. Balachandran S, Venkataraman T, Fisher PB, Barber GN. Fas-associated death domain-containing protein-mediated antiviral innate immune signaling involves the regulation of Irf7. J. Immunol. 178(4), 2429-2439 (2007).
17. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity 22(1), 59-70 (2005).
18. Andrejeva J, Childs KS, Young DF et al. The V proteins of paramyxoviruses bind the IFN-inducible RNA helicase, mda-5, and inhibit its activation of the IFN-β promoter. Proc. Natl Acad Sci. USA 101(49), 17264-17269 (2004).
19. Li K, Foy E, Ferreon JC et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage ot the Toll-like receptor 3 adaptor protein TRIF. Proc. Natl Acad Sci. USA 102(8), 2992-2997 (2005).
20. Foy E, Li K, Sumpter R Jr et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc. Natl Acad. Sci. USA 102(8), 2986-2991 (2005).
21. Assier E, Marin-Esteban V, Haziot A, Maggi E, Charron D, Mooney N. TLR7/ 8 agonists impair monocyte-derived dendritic cell differentiation and maturation. J. Leukoc. Biol. 81 (1), 221-228 (2007).
22. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat. Med. 13(5), 552-559 (2007).
23. Finberg RW, Wang JP, Kurt-Jones EA. Toll like receptors and viruses. Rev. Med. Virol. 17(1), 35-43 (2007).
24. Samanta M, Iwakiri D, Kanda T, Imaizumi T, Takada K. EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN. EMBO J 25(18), 4207-4214 (2006).
25. Alter G, Suscovich TJ, Teigen N et al. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J. Immunol. 178(12), 7658-7666 (2007).
26. Zhu J, Martinez J, Huang X, Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-β. Blood 109(2), 619-625 (2007).
27. Stack J, Haga IR, Schroder M et al. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201(6), 1007-1018 (2005).
28. Lenz P, Lowy DR, Schiller JT. Papillornavirus virus-like particles induce cytokines characteristic of innate immune responses in plasmacytoid dendritic cells. Eur. J. Immunol. 35(5), 1548-1556 (2005).
29. Carter WA, Ventura D, Shapiro DE, Strayer DR, Gillespie DH, Hubbell HR. Mismatched double-stranded RNA, Ampligen (poly(I): poly(C12U), demonstrates antiviral and immunostimulatory activities in HIV disease. Int. J. Immunopharmacol. 13(Suppl. 1), 69-76 (1991).
30. Padalko E, Nuyens D, De Palma A et al. The interferon inducer ampligen [poly(I)-poly(C12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis. Antimicrob. Agents Chemother. 48(1), 267-274 (2004).
31. Gowen BB, Wong MH, Jung KH et al. TLR3 is essential for the induction of protective immunity against Punta Toro Virus infection by the double-stranded RNA (dsRNA), poly(I:C12U), but not Poly(I:C): differential recognition of synthetic dsRNA molecules. J. Immunol. 178(8), 5200-5208 (2007).
32. Ashkar AA, Yao XD, Gin N, Sajic D, Patrick AJ, Rosenthal KL. Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA. J. Infect. Dis. 190(10), 1841-1849 (2004).
33. Schulz O, Diebold SS, Chen M et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433 (7028), 887-892 (2005).
34. Wang JR Asher DR, Chan M, Kurt-Jones EA, Finberg RW. Cutting Edge: Antibody-mediated TLR7-dependent recognition of viral RNA. J. Immunol. 178(6), 3363-3367 (2007).
35. Gorden KB, Gorski KS, Gibson SJ et al. Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8. J. Immunol. 174(3), 1259-1268 (2005).
36. Schon M, Schon MP. The antitumoral mode of action of imiquimod and other imidazoquinolines. Curr. Med. Chem. 14(6), 681-687 (2007).
37. Hattermann K, Picard S, Borgeat M, Leclerc P, Pouliot M, Borgeat P. The Toll-like receptor 7/8-ligand resiquimod (R-848) primes human neutrophils for leukotriene B4, prostaglandin E2 and platelet-activating factor biosynthesis. FASEB J. 21(7), 1575-1585 (2007).
38. Camateros P, Tamaoka M, Hassan M et al. Chronic asthma induced airway remodeling is prevented by the Toll-like receptor 7/8 ligand S28463. Am. J. Respir. Crit. Care Med. 175(12), 1241-1249 (2007).
39. Vidal D. Topical imiquimod: mechanism of action and clinical applications. Mini Rev. Med. Chem. 6(5), 499-503 (2006).
40. Theos AU, Cummins R, Silverberg NB, Paller AS. Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. Cutis 74(2), 134-142 (2004).
41. Schacker TW, Conant M, Thoming C, Stanczak T, Wang Z, Smith M. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a Phase II, randomized, double-blind, placebo-controlled study. Antimicrob. Agents Chemother. 46(10), 3243-3248 (2002).
42. Spruance SL, Tyring SK, Smith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J. Infect. Dis. 184(2), 196-200 (2001).
43. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006).
44. Kerkmann M, Lochmann D, Weyermann J. et al. Immunostimulatory properties of CpG-oligonucleotides are enhanced by the use of protamine nanoparticles. Oligonucleotides 16(4), 313-322 (2006).
45. De Clercq E. Antiviral drugs in current clinical use. J. Clin. Virol. 30(2), 115-133 (2004).
46. Agrawal S, Martin RR. Was induction of HIV-1 through TLR9? J. Immunol. 171(4), 1621 (2003).
47. Schlaepfer E, Audige A, von Beust B et al. CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J. Virol. 78(22), 12344-12354 (2004).
48. McCluskie MJ, Cartier JL, Patrick AJ et al. Treatment of intravaginal HSV-2 infection in mice: a comparison of CpG oligodeoxynucleotides and resiquimod (R-848). Antiviral Res. 69(2), 77-85 (2006).
49. Dorn A, Ludwig RJ, Bock A et al. Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. J Invest. Dermatol. 127(4), 846-854 (2007).
50. Vabulas RM, Ahmad-Nejad P, da Costa C et al. Endocytosed Hsp60s use Toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/ interleukin-1 receptor signaling pathway in innate immune cells. J. Biol. Chem. 276(33), 31332-31339 (2001).
51. Koi A, Lichtman AH, Finberg RW, Libby P, Kurt-Jones EA. Cutting edge: heat shock protein (Hsp) 60 activates the innate immune response: CD14 is an essential receptor for Hsp60 activation of mononuclear cells. J. Immunol. 164(1), 13-17 (2001).
52. Becker T, Hartl FU, Wieland F. CD40, an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J. Cell Biol. 158(7), 1277-1285 (2002).
53. Binder RJ, Han DK, Srivastava PK. CD91: a receptor for heat shock protein, gp96. Nat. Immunol. 1(2), 151-155 (2000).
54. Delneste Y, Magistrelli G, Gauchat J et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17(3), 353-362 (2002).
55. + T cells in vivo. Proc. Natl Acad. Sci. USA 91(8), 3077-3081 (1994).
56. Heikema A, Agsteribbe E, Wilschut J, Huckriede A. Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides. Immunol. Lett. 57(1-3) 69-74 (1997).
57. Zugel U, Sponaas AM, Neckermann J, Schoel B, Kaufmann SH. gp96-peptide vaccination of mice against intracellular bacteria. Infect. Immun. 69(6), 4164-4167 (2001).
58. Suzue K, Young RA. Heat shock proteins as immunological carriers and vaccines. EXS77, 451-465 (1996).
59. Hoos A, Levey DL. Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications. Expert Rev. Vaccines 2(3), 369-379 (2003).
60. Palefsky JM, Berry IM, Jay N et al. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals. AIDS 20 (8), 1151-1155 (2006).
61. von Nida J, Quirk C. Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene. Australas. J. Dermatol. 44(4), 277-280 (2003).
62. Liu SJ, Tsai JR Shen CR et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-f{β} and interleukin-6. J. Leukoc. Biol. (2007) (Epub ahead of print).
63. + IL-17-producing T cells are important in effector functions for the elicitation of contact hypersensitivity responses. J. Immunol. 177(10), 6852-6858 (2006).
64. Zhang Z, Andoh A, Inatomi O et al. Interleukin-17 and lipopolysaccharides synergistically induce cyclooxygenase-2 expression in human intestinal myofibroblasts. J. Gastroenterol. Hepatol. 20(4), 619-627 (2005).
65. + T cells with protection against rotavirus shedding in mice intranasally immunized with VP6 and the adjuvant LT(R192G). J. Virol. 81(8), 3740-3748 (2007).
66. Pestka J, Zhou HR. Toll-like receptor priming sensitizes macrophages to proinflammatory cytokine gene induction by deoxynivalenol and other toxicants. Toxicol. Sci. 92(2), 445-455 (2006).
67. Aiba S, Katz SI. Phenotypic and functional characteristics of in vivo-activated Langerhans cells. J. Immunol. 145(9), 2791-2796 (1990).
68. Iijima N, Yanagawa Y, Once K. Role of early- or late-phase activation of p38 mitogen-activated protein kinase induced by tumour necrosis factor-α or 2,4-dinitrochlorobenzene during maturation of murine dendritic cells. Immunology 110(3), 322-328 (2003).
69. Boisleve F, Kerdine-Romer S, Rougier-Larzat N, Pallardy M. Nickel and DNCB induce CCR7 expression on human dendritic cells through different signalling pathways: role of TNF-α and MAPK. J. Invest. Dermatol. 123(3), 494-502 (2004).
70. Ebner S, Lenz A, Reider D, Fritsch P, Schuler G, Romani N. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin. Immunobiology 198(5) 568-587 (1998).
71. Staquet MJ, Sportouch M, Jacquet C, Schmitt D, Guesnet J, Peguet-Navarro J. Moderate skin sensitizers can induce phenotypic changes on in vitro generated dendritic cells. Toxicol. In Vitro. 18(4), 493-500 (2004).
72. Schwarzenberger, K, Udey, MC. Contact allergens and epidermal proinflammatory cytokines modulate Langerhans cell E-cadherin expression in situ. J. Invest. Dermatol. 106(3), 553-558 (1996).
73. Weiss JM, Sleeman J, Renkl AC et al. An essential role for CD44 variant isoforms in epidermal Langerhans cell and blood dendritic cell function. J. Cell Biol. 137(5), 1137-1147 (1997).
74. Aiba S, Nakagawa S, Ozawa H, Miyake K, Yagita H, Tagami H. Up-regulation of α 4 integrin on activated Langerhans cells: analysis of adhesion molecules on Langerhans cells relating to their migration from skin to draining lymph nodes. J. Invest. Dermatol. 100(2), 143-147 (1993).
75. Kobayashi Y. Langerhans' cells produce type IV collagenase (MMP-9) following epicutaneous stimulation with haptens. Immunology 90(4), 496-501 (1997).
76. Martin SF. T lymphocyte-mediated immune responses to chemical haptens; and metal ions: implications for allergic and autoimmune disease. Int. Arch. Allergy Immunol. 134(3), 186-198 (2004).
77. Ribas A, Butterfield LH, Glaspy JA, Economou JS. Current developments in cancer vaccines and cellular immunotherapy. J. Clin. Oncol. 21(12), 2415-2432 (2003).
78. O'Neill D, Bhardwaj N. Generation of autologous peptide- and protein-pulsed dendritic cells for patient-specific immunotherapy. Methods Mol. Med. 109, 97-112 (2005).
79. Lewis HM. Topical immunotherapy of refractory warts. Cutis 12, 863-867 (1973).
80. Upitis JA, Krol A. The use of dipheny1cyclopropenone in the treatment of recalcitrant warts. J. Cutan. Med Surg. 6(3), 214-217 (2002).
81. Orecchia G, Douville H, Santagostino L, Rabbiosi G. Treatment of multiple relapsing warts with diphenciprone. Dermatologica 177(4), 225-231 (1988).
82. Puig L, Alegre M, Cuatrecasas M, De Moragas JM. Erythema multiforme-like reaction following diphencyprone treatment of plane warts. Int. J. Dermatol. 33(3), 201-203 (1994).
83. Johansson E, Forstrom L. Dinitrochlorbenzene (DNCB) treatment of viral warts. A 5-year follow-up study. Acta Derm. Venereol. 64(6), 529-533 (1984).
84. Petrelli R, Cotlier E, Robins S, Stoessel K. Dinitrochlorobenzene immunotherapy of recurrent squamous papilloma of the conjunctiva. Ophthalmology 88(12), 1221-1225 (1981).
85. Dall'Oglio F, Nasca MR, D'Agata O, Micali G. Adult and paediatric contact immunotherapy with squaric acid dibutylester (SADBE) for recurrent, multiple, resistant, mucocutaneous anogenital warts. Sex Transm. Infect. 78(4), 309-310 (2002).
86. Naylor MF, Neldner KH, Yarbrough GK, Rosio TJ, Iriondo M, Yeary J. Contact immunotherapy of resistant warts. J. Am. Acad. Dermatol. 19(4), 679-683 (1988).
87. Rampen FH, Steijlen PM. Diphencyprone in the management of refractory palmoplantar and periungual warts: an open study. Dermatology 193 (3), 236-238 (1996).
88. Micali G, Dall'Oglio F, Tedeschi A, Pulvirenti N, Nasca MR. Treatment of cutaneous warts with squaric acid dibutylester: a decade of experience. Arch. Dermatol. 136(4), 557-558 (2000).
89. Weisshaar E, Neumann HJ, Gollnick H, Successful treatment of disseminated facial verrucae with contact immunotherapy. Eur. J. Dermatol. 8(7), 488-491 (1998).
90. Pollock B, Higher AS. An interesting response to diphencyprone (DPC) sensitization on facial warts: review of DPC treatment for viral warts. J. Dermatolog. Treat. 13(2), 47-50 (2002).
91. Georgala S, Danopoulou I, Katsarou A. Dinitrochlorobenzene treatment of condylomata acuminata. Australas. J. Dermatol. 30(2), 103-105 (1989).
92. Guthrie D, Way S. Immunotherapy of non-clinical vaginal cancer. Lancet 2(7947), 1242-1243 (1975).
93. Levis WR, Holzer AM, Leonard LK. Topical diphenylcyclopropenone as a measure of immune competence in HIV-seropositive subjects. J. Drugs Dermatol. 5(9), 853-858 (2006).
94. Callard RE. Decision-making by the immune response. Immunol. Cell. Biol. 85(4), 300-305 (2007).
95. + regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
96. Kastelein RA, Hunter CA, Cua DJ. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annu. Rev. Immunol. 25, 221-242 (2007).
97. Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Annu. Rev. Immunol. 25, 821-852 (2007).
98. 7 T helper cells. Cell 126(6), 1121-1133 (2006).
99. Bettelli E, Carrier Y, Gao W et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441(7090), 235-238 (2006).
100. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 24 (6), 677-688 (2006).
101. + T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol. 8(4), 369-377 (2007).
102. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24(2), 179-189 (2006).
103. Ye P, Rodriguez FH, Kanaly S et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J. Ep. Med. 194 (4), 519-527 (2001).
104. Mangan PR, Harrington LE, O'Quinn DB et al. Transforming growth factor-β induces development of the T(H) 17 lineage. Nature 441(7090), 231-234 (2006).
105. Leibundgut-Landmann S, Gross O, Robinson MJ et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat. Immunol. 8(6), 630-638 (2007).
106. Maek-A-Nantawat W, Buranapraditkun S, Klaewsongkram J, Ruxrungthum K. Increased interleukin-17 production both in helper T cell subset Th17 and CD4-negative T cells in human immunodeficiency virus infection. Viral Immunol. 20(1), 66-75 (2007).